Radiopaedia Helpers

yttrium-90-ibritumomab-tiuxetan

Headings Spacing

error

"Characteristics "

Line 2:1 · Never put spaces at either end of headings.

"Use "

Line 15:1 · Never put spaces at either end of headings.

"Potential side effects "

Line 18:1 · Never put spaces at either end of headings.

Acronyms

warning

"Yttrium-90 ibritumomab tiuxetan, also known by the trade name Zevalin (Acrotech Biopharma LLC, USA), is a theranostic radiopharmaceutical approved for the treatment of patients with relapsed or refractory low-grade or follicular non-Hodgkin lymphoma (NHL). More specifically, it is a radioimmunotherapy that uses an antibody, ibritumomab, against the B-cell antigen CD20, which is present in more than 90% of NHL tumour cells. The chelate tiuxetan binds the antibody to the beta-particle-emitting Yttrium-90, enabling the targeted delivery of the beta-emitter to cancer cells for their destruction."

Line 1:133 · 'USA' has no definition. Spell it out if it's unfamiliar to the audience.

"Ibritumomab tiuxetan as an antibody treatment, as well as conjugated to Indium III and Yttrium 90, were approved by the FDA in February 2002 for the treatment of refractory follicular non-Hodgkin's lymphoma."

Line 31:124 · 'FDA' has no definition. Spell it out if it's unfamiliar to the audience.

"Another FDA approved radioimmunotherapy used to treat non-Hodgkin lymphoma is iodine-131 tositumomab (tradename Bexxar). In the United States, Bexxar has not been produced since February 2014."

Line 32:12 · 'FDA' has no definition. Spell it out if it's unfamiliar to the audience.

Strong

warning

"Characteristics "

Line 2:5 · Generally, don't use bold in text: 'Characteristics '

"This treatment regimen is given between 6 and 12 months after the last dose of standard chemotherapy. One dose of non-radiolabeled rituximab is given intravenously. Rituximab binds to CD20 receptors in the blood and spleen, saturating these normal sites of uptake. Premedication with oral paracetamol and diphenhydramine is recommended. Seven to nine days after this first infusion, an additional dose of Rituximab is administered. Four hours after this dose, Y-90 ibritumomab tiuxetan is then administered intravenously at a dose of 0.4 mCi/kg (14.8 MBq per kg) Y-90 for patients with normal platelet count to a maximum dose of 32 mCi (1184 MBq). A reduced dose of 0.3 mCi/kg (11.1 MBq per kg) Y-90 ibritumomab tiuxetan intravenous infusion should be administered if platelet count is between 100,000 and 150,000/mm³."

Line 17:4 · Generally, don't use bold in text: 'This treatment regimen is given between 6 and 12 months after the last dose of standard chemotherapy. One dose of non-radiolabeled rituximab is given intravenously. Rituximab binds to CD20 receptors in the blood and spleen, saturating these normal sites of uptake. Premedication with oral paracetamol and diphenhydramine is recommended. Seven to nine days after this first infusion, an additional dose of Rituximab is administered. Four hours after this dose, Y-90 ibritumomab tiuxetan is then administered intravenously at a dose of 0.4 mCi/kg (14.8 MBq per kg) Y-90 for patients with normal platelet count to a maximum dose of 32 mCi (1184 MBq). A reduced dose of 0.3 mCi/kg (11.1 MBq per kg) Y-90 ibritumomab tiuxetan intravenous infusion should be administered if platelet count is between 100,000 and 150,000/mm'

List Caps

warning

"Y-90 half-life of 64.2 hours"

Line 4:8 · In general, we don't start a list item with a capital letter. Exceptions are proper nouns.

Headings Valid

warning

Expected headings